BHV-7000

Phase 2Small molecule

BHV-7000 is one of 79 small molecule programs targeting Epilepsy With Generalized Tonic-Clonic Seizures. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epilepsy With Generalized Tonic-Clonic SeizuresActive, not recruiting

EpilepsyActive, not recruiting

Major Depressive DisorderActive, not recruiting

Focal EpilepsyActive, not recruiting

Epilepsy With Generalized Tonic-Clonic SeizuresPhase 2/Phase 3

Active, not recruiting

EpilepsyPhase 2/Phase 3

Active, not recruiting

Major Depressive DisorderPhase 2

Active, not recruiting

Focal EpilepsyPreclinical

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 2

Risperdal

WWim Janssens

Phase 3

2 3

Fetzima

AbbVie

Phase 3

9 4

Lisdexamfetamine Dimesylate

Takeda

Phase 3

1 5

SPD489

Takeda

Phase 3

3 6

Seroquel IR

Otsuka

Phase 3

1 7

Antidepressant Therapy

AbbVie

Phase 3

4 8

Saredutant

Sanofi

Phase 3

3 9

CYB003

CCybin IRL Limited

Phase 3

3 10

Minocyclin

UUniversity of Southern California

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Focal Epilepsy

NCT06309966

Phase 2/3Recruiting

Epilepsy

NCT06132893

Clinical

Trials by Indication[1]

Epilepsy1 trial

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting·BBiohaven Therapeutics Ltd.·Phase 2/3·NCT06132893·390 enrolled

Epilepsy With Generalized Tonic-Clonic Seizures1 trial

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

Terminated·BBiohaven Therapeutics Ltd.·Phase 2/3·NCT06425159·27 enrolled

Phase 11 trial

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

Enrolling by invitation·BBiohaven Therapeutics Ltd.·Phase 1·NCT07262268·5 enrolled

Treatment1 trial

BHV-7000 Acute Treatment of Bipolar Mania

Completed·BBiohaven Therapeutics Ltd.·Phase 2/3·NCT06419582·274 enrolled

Major Depressive Disorder1 trial

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

Enrolling by invitation·BBiohaven Therapeutics Ltd.·Phase 2·NCT06423781·480 enrolled

3 more indications

Efficacy and Safety1 trial

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Completed·BBiohaven Therapeutics Ltd.·Phase 2·NCT06419608·336 enrolled

Focal Epilepsy1 trial

A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Active, not recruiting·BBiohaven Therapeutics Ltd.·Preclinical·NCT06309966·390 enrolled

Unspecified2 trials

BHV-7000 Open-Label Extension Bipolar Mania Study

Terminated·BBiohaven Therapeutics Ltd.·Phase 2·NCT06423794·94 enrolled

Long-term Safety and Tolerability of BHV-7000

Enrolling by invitation·BBiohaven Therapeutics Ltd.·Phase 2·NCT06443463·660 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for BHV-7000. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BHV-7000 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BHV-7000. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biohaven Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiohaven Therapeutics Ltd.

BHV-7000

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Epilepsy1 trial

Epilepsy With Generalized Tonic-Clonic Seizures1 trial

Phase 11 trial

Treatment1 trial

Major Depressive Disorder1 trial

Efficacy and Safety1 trial

Focal Epilepsy1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News